Published in Oncoimmunology on August 01, 2012
Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis. PLoS One (2013) 0.75
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest (2017) 0.75
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature (1988) 2.15
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol (2010) 1.71
The role of granulocytes following intravesical BCG prophylaxis. Eur Urol (2006) 1.54
Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 1.52
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16
Role of the immune response in BCG for bladder cancer. Eur Urol (1992) 1.07
Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother (2004) 1.03
Bladder cancer: a review of diagnosis and management. J Natl Med Assoc (2000) 0.95
Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer (2010) 0.94
Flow cytometric analysis of urine lymphocytes isolated from patients with renal transplants--purification of urine lymphocytes. J Immunol Methods (1998) 0.90
Isolation and characterisation of T lymphocytes from the urethra of patients with acute urethritis. Sex Transm Infect (1998) 0.87
Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. Clin Vaccine Immunol (2008) 0.84
Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. Oncoimmunology (2012) 0.82
Management of carcinoma in situ of the bladder: the case for surgical management. Urol Clin North Am (1980) 0.82
The immunotherapy of prostate and bladder cancer. BJU Int (2005) 0.80
Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses. Methods Mol Biol (2010) 0.78
Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocr Relat Cancer (2013) 1.49
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med (2006) 1.26
Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr (2013) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol (2007) 1.23
Management of cryptorchidism in children: guidelines. Swiss Med Wkly (2008) 1.15
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res (2006) 1.11
Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation. J Biol Chem (2002) 1.09
Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine (2008) 1.07
Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine (2006) 1.04
Evaluation of the CFP-substrate-YFP system for protease studies: advantages and limitations. Biotechniques (2004) 1.00
A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer (2011) 0.99
Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol (2004) 0.99
Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun (2008) 0.95
Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer (2011) 0.95
Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer (2010) 0.94
Metastatic primary adenocarcinoma of the bladder in a twenty-five years old woman. Rare Tumors (2011) 0.93
Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research. Clin Microbiol Rev (2014) 0.92
Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs. PLoS Negl Trop Dis (2012) 0.91
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol (2007) 0.90
Bladder cancer documentation of causes: multilingual questionnaire, 'bladder cancer doc'. Front Biosci (Elite Ed) (2012) 0.90
Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect Immun (2004) 0.89
Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine (2009) 0.89
Cryopreservation of prostate cancer tissue during routine processing of fresh unfixed prostatectomy specimen: demonstration and validation of a new technique. Prostate (2009) 0.86
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res (2007) 0.86
Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. Clin Vaccine Immunol (2008) 0.84
Treatment of penile carcinoma: to cut or not to cut? Int J Radiat Oncol Biol Phys (2006) 0.83
Identification of a new SERCA2 splice variant regulated during monocytic differentiation. Biochem Biophys Res Commun (2003) 0.83
Are patients at nutritional risk more prone to complications after major urological surgery? J Urol (2013) 0.83
Prevention of renal infection and urinary shedding in dogs by a Leptospira vaccination. Vet Microbiol (2005) 0.83
The importance of mucosal immunity in defense against epithelial cancers. Curr Opin Immunol (2005) 0.83
International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine (2011) 0.83
Percutaneous drainage and sclerotherapy as definitive treatment of renal lymphangiomatosis. Can Urol Assoc J (2012) 0.82
Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates. Int J Public Health (2009) 0.82
Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem (2005) 0.82
Can 3T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension? Can Urol Assoc J (2013) 0.81
Ex vivo ultrasound control of resection margins during partial nephrectomy. J Urol (2011) 0.81
Protective Efficacy of the Calicivirus Valency of the Leucofeligen Vaccine against a Virulent Heterologous Challenge in Kittens. Vet Med Int (2013) 0.80
Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Res Bull (2006) 0.80
Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur J Biochem (2004) 0.80
Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells. Int J Cancer (2006) 0.79
Profiling of proteolytic activities secreted by cancer cells using phage display substrate technology. Tumour Biol (2004) 0.78
Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells. Oncoimmunology (2013) 0.78
Well-differentiated papillary mesothelioma of the tunica vaginalis testis: imaging on Tc-99m heat-denatured red blood cell scintigraphy. Clin Nucl Med (2008) 0.78
Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther (2014) 0.77
Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J (2006) 0.76
[Screening of the prostate cancer. "lnstantaneous" of a daily practice among 300 general practitioners of the canton of Vaud]. Rev Med Suisse (2005) 0.76
Investigation of an inducible nitric oxide synthase gene (NOS2A) polymorphism in a multiple sclerosis population. Brain Res Bull (2004) 0.76
What is the influence of vaccination's routes on the regression of tumors located at mucosal sites? Oncoimmunology (2012) 0.75
[Male circumcision: a banality?]. Rev Med Suisse (2012) 0.75
[Role of the urologist in the screening of bone diseases]. Rev Med Suisse (2010) 0.75
High-magnification vascular imaging to reject false-positive sites in situ during Hexvix® fluorescence cystoscopy. J Biomed Opt (2010) 0.75
[The urologist at the center of the expected progress on the management of localized prostate cancer!]. Rev Med Suisse (2010) 0.75
[Urologic treatment of lithiasis]. Rev Med Suisse Romande (2004) 0.75
[Prostate cancer screening: utility, goals and perspectives in 2010]. Rev Med Suisse (2010) 0.75
[Gender disparities in urologic cancers]. Rev Med Suisse (2015) 0.75
[Urology]. Rev Med Suisse (2015) 0.75
[Urology, a changing specialty]. Rev Med Suisse (2009) 0.75
[Biochemical failure after curative treatment for localized prostate cancer]. Rev Med Suisse (2005) 0.75
[Urinary incontinence in women: management in primary care]. Rev Med Suisse (2008) 0.75
[Trends in urology]. Rev Med Suisse (2008) 0.75
[Fluorescence guided endoscopy: improvement in the management of bladder cancer]. Rev Med Suisse (2010) 0.75
Experimental evaluation of an electromechanical artificial urinary sphincter in an animal model. BJU Int (2013) 0.75
[Robotics and medicine: what's in the future?]. Rev Med Suisse (2007) 0.75
[Focal therapy in prostate cancer: rationale, results and perspectives]. Rev Med Suisse (2014) 0.75
[In Process Citation]. Rev Med Suisse (2015) 0.75
Antibody response to vaccines for rhinotracheitis, caliciviral disease, panleukopenia, feline leukemia, and rabies in tigers (Panthera tigris) and lions (Panthera leo). J Zoo Wildl Med (2012) 0.75
Hexyl-aminolevulinate-mediated photodynamic therapy: how to spare normal urothelium. An in vitro approach. Lasers Surg Med (2007) 0.75
[Novelties in Urology in 2015]. Rev Med Suisse (2016) 0.75
Images in clinical urology. Nail of glans penis. Urology (2009) 0.75
[Prostate biopsy: which strategy for which patient?]. Rev Med Suisse (2015) 0.75
[Second and third-lines therapy for the management of erectile dysfunction]. Rev Med Suisse (2015) 0.75
SITC 26th annual meeting--summary. J Transl Med (2012) 0.75
[Cysteine lithiasis]. Rev Med Suisse Romande (2004) 0.75
[Syringocele: a case report]. Prog Urol (2007) 0.75
[Multimodal surgical management of stones in the upper urinary tract]. Rev Med Suisse (2014) 0.75
[The aging male: a global approach to late onset hypogonadism and erectile dysfunction]. Rev Med Suisse (2014) 0.75
[Benefits of ultrasonography in kidney and testicular-sparing surgery]. Rev Med Suisse (2010) 0.75
De novo concurrent papillary renal cell carcinoma and angiomyolipoma in a kidney allograft: evidence of donor origin. Hum Pathol (2006) 0.75
[Indications and methods of invasive minimal urinary derivations in oncology]. Rev Med Suisse (2007) 0.75
[To act with professionalism]. Rev Med Suisse (2014) 0.75
[Infective lithiasis]. Rev Med Suisse Romande (2004) 0.75
[Homage to Professor Hans-Jürg Leisinger]. Rev Med Suisse (2012) 0.75
[Sharing uncertainties of prostate cancer screening]. Rev Med Suisse (2015) 0.75